Welcome to our dedicated page for Ovid Therapeutics SEC filings (Ticker: OVID), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ovid Therapeutics Inc. filings document a Nasdaq-listed biopharmaceutical company focused on small-molecule medicines for CNS disorders involving neuronal hyperexcitability. Its regulatory record includes 8-K disclosures for clinical program updates, operating and financial results, leadership and compensation arrangements, Nasdaq compliance, and capital-structure events involving common stock, preferred stock, warrants and pre-funded warrants.
Proxy statements disclose board and executive governance, equity compensation, shareholder meeting proposals, authorized-share matters, and stockholder votes required under Nasdaq rules for securities issuances. The filings also record material agreements, risk and governance subjects, and exhibits related to the company’s OV350, OV4071 and OV329 development programs.
Bernstein Karen reported acquisition or exercise transactions in this Form 4 filing.
Ovid Therapeutics director Karen Bernstein was granted employee stock options covering 65,000 shares of Ovid common stock. The award was made on February 26, 2026 and is reported at a grant price of $0.00 per share in this filing.
According to the terms, the option will vest in full on February 26, 2027, as long as Bernstein continues to provide service to the company through that date. After vesting, the option will become exercisable for the underlying shares, subject to the company’s equity plan and any applicable restrictions.
Ovid Therapeutics Inc. chief business and financial officer Rona Jeffrey reported a mix of equity grants and a small tax-related sale. On February 26, 2026, Jeffrey received an option to purchase 408,750 shares of Common Stock and a grant of 68,125 shares of Common Stock as a restricted stock unit award, both at a price per share of $0.00. The RSUs vest in three equal annual installments beginning February 20, 2027, and the stock options vest in 48 equal monthly installments beginning March 20, 2026, conditioned on continued service.
On February 23, 2026, Jeffrey sold 8,541 shares of Common Stock at a weighted average price of $1.45 per share. According to the disclosure, this sale was a mandatory “sell to cover” transaction to satisfy statutory tax withholding obligations triggered by restricted stock unit vesting, not a discretionary sale decision.
Ovid Therapeutics Inc. Schedule 13G discloses that ADAR1-related parties report beneficial ownership of 9,284,166 shares of Common Stock, equal to 6.9% of the class. The filing attributes these holdings to ADAR1 Capital Management, ADAR1 Capital Management GP and Daniel Schneeberger and ties the percentage to December 15, 2025, based on 130,184,353 shares outstanding reported in the issuer's prospectus.
Ovid Therapeutics Inc. received an updated ownership report from Affinity Asset Advisors, LLC and Michael Cho. The reporting persons beneficially own 12,149,166 shares of Ovid common stock, including 4,999,166 shares issuable upon exercise of warrants, representing approximately 9.0% of the outstanding common stock.
The securities are held through Affinity Healthcare Fund, LP, over which Affinity Asset Advisors acts as investment manager and Michael Cho is the managing member. The filers state the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Ovid.
Federated Hermes, Inc. and related parties have filed a Schedule 13G reporting beneficial ownership of 7,737,166 shares of Ovid Therapeutics Inc. common stock, representing 5.94% of the class as of the 12/31/2025 event date. Federated Hermes and the Voting Shares Irrevocable Trust report sole voting and dispositive power over these shares, while individuals Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue report shared voting and dispositive power over the same 7,737,166 shares.
The reporting persons state that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Ovid Therapeutics. Federated Hermes, the trust, and the individual filers expressly disclaim beneficial ownership of securities held by the managed funds referenced in the filing.
Federated Hermes, Inc. and related parties have filed a Schedule 13G reporting beneficial ownership of 7,737,166 shares of Ovid Therapeutics Inc. common stock, representing 5.94% of the class as of the 12/31/2025 event date. Federated Hermes and the Voting Shares Irrevocable Trust report sole voting and dispositive power over these shares, while individuals Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue report shared voting and dispositive power over the same 7,737,166 shares.
The reporting persons state that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Ovid Therapeutics. Federated Hermes, the trust, and the individual filers expressly disclaim beneficial ownership of securities held by the managed funds referenced in the filing.
Ovid Therapeutics Inc.'s CEO and director reported a set of insider transactions involving preferred stock, warrants, and common shares. On December 11, 2025, the reporting person purchased 71 investment units at $1,400 per unit, each unit consisting of one share of Series B Convertible Preferred Stock, one Series A Warrant to purchase 666.66 shares of common stock, and one Series B Warrant to purchase 500 shares of common stock.
Each share of Series B Convertible Preferred Stock automatically converted into 1,000 shares of common stock at 5 p.m. Eastern Time on December 15, 2025, resulting in 71,000 common shares after stockholder approval on December 11, 2025. Following these transactions, the reporting person directly beneficially owned 3,687,715 common shares and indirectly held 35,461 common shares through Divo Holdings, LLC, while disclaiming beneficial ownership of those indirect shares.
Ovid Therapeutics Inc. reported that it has released new information on its experimental therapy OV350. The company issued a press release announcing results from its Phase 1 study of OV350, an early-stage clinical trial that primarily evaluates safety, dosing, and how the drug behaves in the body. The press release, dated December 18, 2025, is attached as an exhibit to this report for investors and the public to review.
Ovid Therapeutics Inc. has filed a Form S-3 prospectus to register for resale up to 125,064,325 shares of its common stock held by existing investors. These shares come from 57,722,000 shares issued upon the automatic conversion of Series B preferred stock on December 15, 2025, 38,481,325 shares issuable upon exercise of Series A warrants, 28,861,000 shares issuable upon exercise of Series B warrants, and any shares issued from related pre-funded warrants.
The company is not selling any shares in this offering and will not receive proceeds from sales made by the selling stockholders. The registration fulfills obligations under an October 2025 private placement and allows these investors to sell their shares over time through various public or private transactions. Shares outstanding were 130,184,353 as of December 15, 2025; this is a baseline figure, not the amount being registered.
Ovid Therapeutics Inc. reported Q3 2025 results. Revenue was $132k in the quarter and $6.534M year‑to‑date, primarily from license and other revenue. Operating expenses were $12.655M, led by research and development of $5.87M and general and administrative of $6.785M, resulting in a net loss of $12.158M (basic and diluted loss per common share $0.17).
As of September 30, 2025, cash, cash equivalents and marketable securities totaled $25.6M. Net cash used in operating activities was $27.9M for the nine months. Subsequent to quarter‑end, the company closed a private placement of convertible preferred stock and warrants for net proceeds of $75.7M, and stated that available liquidity, including these proceeds, is sufficient to fund operations for more than 12 months after issuance of these financial statements.
Shares outstanding were 71,212,353 as of November 7, 2025.